Does LUTETIUM LU-177 Cause Second primary malignancy? 5 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Second primary malignancy have been filed in association with LUTETIUM LU-177. This represents 4.4% of all adverse event reports for LUTETIUM LU-177.
5
Reports of Second primary malignancy with LUTETIUM LU-177
4.4%
of all LUTETIUM LU-177 reports
0
Deaths
4
Hospitalizations
How Dangerous Is Second primary malignancy From LUTETIUM LU-177?
Of the 5 reports, 4 (80.0%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LUTETIUM LU-177. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does LUTETIUM LU-177 Cause?
Malignant neoplasm progression (39)
Fatigue (35)
Diarrhoea (29)
Abdominal pain (19)
Asthenia (19)
Vomiting (19)
Blood pressure increased (18)
Body temperature decreased (18)
Drug ineffective (18)
Blood pressure systolic increased (17)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which LUTETIUM LU-177 Alternatives Have Lower Second primary malignancy Risk?
LUTETIUM LU-177 vs LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
LUTETIUM LU-177 vs LUTETIUM OXODOTREOTIDE LU-177
LUTETIUM LU-177 vs LUTROPIN ALFA
LUTETIUM LU-177 vs LYMECYCLINE
LUTETIUM LU-177 vs LYRICA